Breitenlechner Christine, Gassel Michael, Engh Richard, Bossemeyer Dirk
Abteilung Strukturforschung, Max-Planck-Institut fuer Biochemie, D-82152 Martinsried, Germany.
Oncol Res. 2004;14(6):267-78. doi: 10.3727/096504003773994806.
The AGC group of protein kinases comprises several targets for small molecule inhibitors of therapeutic significance. Crystal structure data facilitate the design or improvement of selective inhibitory molecules. Cross-selectivity of kinase inhibitors is often observed among closely related enzymes. Usually an obstacle for inhibitor design, cross-selectivity can be useful to obtain structural data from a related kinase, if not available from the original target. Protein kinase A (PKA), a representative of the AGC kinase group, has been cocrystallized with AGC group inhibitors from diverse chemical groups, thus providing structural information about binding modes, selectivity, and cross-selectivity. "Ersatz" kinases were created by mutating the inhibitor binding site of PKA to resemble other related kinases from the AGC group. The cocrystallization of these ersatz kinases with certain AGC group small molecule inhibitors elucidated some aspects of protein kinase inhibitor selectivity in this group of kinases.
蛋白激酶AGC组包含几个具有治疗意义的小分子抑制剂靶点。晶体结构数据有助于设计或改进选择性抑制分子。激酶抑制剂的交叉选择性在密切相关的酶之间经常被观察到。交叉选择性通常是抑制剂设计的一个障碍,但如果从原始靶点无法获得相关激酶的结构数据,交叉选择性可用于获取该相关激酶的结构数据。蛋白激酶A(PKA)是AGC激酶组的代表,已与来自不同化学基团的AGC组抑制剂共结晶,从而提供了有关结合模式、选择性和交叉选择性的结构信息。通过突变PKA的抑制剂结合位点来创建“替代”激酶,使其类似于AGC组中的其他相关激酶。这些替代激酶与某些AGC组小分子抑制剂的共结晶阐明了该组激酶中蛋白激酶抑制剂选择性的一些方面。